Surface Oncology

Surface Oncology developed novel antibody immunotherapy candidates designed to modulate elements at the boundary of the innate and adaptive immune systems within the tumor micro-environment. Their approach involved identifying and targeting specific pathways to overcome tumor immunosuppression, with lead assets including SRF388, an IL-27-targeted antibody, and Casdozokitug (SRF114), an anti-IL-27 antibody. These therapies aim to enhance the body's natural defenses against various cancers.

The company was founded in 2014 by a team of experienced scientific leaders who recognized the potential of novel immune checkpoints and pathways to create effective cancer treatments. This insight led to the creation of a pipeline focused on next-generation immuno-oncology, leveraging a deep understanding of tumor biology and immunological mechanisms to develop differentiated therapeutics.

Surface Oncology’s therapies are intended for cancer patients who can benefit from advanced immuno-oncology treatments. The company’s long-term vision was to significantly transform cancer care by extending patient survival and improving outcomes through its targeted antibody therapeutics. Its pipeline assets now contribute to a larger immuno-oncology portfolio, continuing the pursuit of innovative cancer solutions.

Surface Oncology is a clinical‑stage immuno‑oncology company (now a Coherus BioSciences subsidiary) that developed next‑generation antibody therapies targeting the tumor microenvironment to enhance anti‑tumor immune responses.[3][5]

High‑Level Overview

• Mission: Surface sought to deliver transformative outcomes for cancer patients by targeting biological pathways in the immunosuppressive tumor microenvironment (TME) to broaden and deepen responses to immunotherapy.[2][3]
  - Investment philosophy (for an investor profile — note Surface itself was a portfolio company backed by life‑science investors): F‑Prime and other life‑science investors supported Surface’s strategy of advancing multiple antibody programs that engage both innate and adaptive immunity, privileging programs with strong translational biology and partnership potential.[1][3]
  - Key sectors: Oncology biologics / immuno‑oncology, antibody therapeutics, tumor microenvironment biology.[3][2]
  - Impact on the startup ecosystem: Surface exemplified a TME‑focused biotech that translated mechanistic oncology discovery into multiple clinic‑stage assets and attracted strategic pharma collaborations and ultimately an acquisition, demonstrating a pathway for specialty oncology startups to de‑risk programs via partnerships and exit to larger commercial biopharma.[3][5]

As a portfolio company (concise): Surface built antibody immunotherapies (e.g., SRF388/“casdozo” targeting IL‑27; SRF617 targeting CD39; NZV930/CD73 collaborations; SRF114/CCR8) for oncology indications, serving oncologists and cancer patients by attempting to convert immunologically “cold” tumors into responsive ones via TME modulation, and it demonstrated clinical‑stage progress and partner interest that culminated in acquisition by Coherus BioSciences.[4][3][5]

Origin Story

• Founding year and early backing: Surface Oncology was incorporated in 2014 and was backed by venture and life‑science investors (including F‑Prime among its investors).[3][1]
  - Founders/background and idea emergence: The company was founded by scientists and industry executives focused on translating deep biology of the tumor microenvironment into antibody therapeutics; its scientific strategy emphasized targeting multiple suppressive pathways (innate and adaptive) because first‑generation checkpoint inhibitors benefit only a subset of patients.[2][3]
  - Early traction/pivotal moments: Surface advanced multiple programs into clinical development (SRF388 into Phase II and SRF114 into Phase I/II) and established collaborations with larger pharma (Novartis on CD73, GSK on PVRIG/CD112R), milestones that increased strategic value and led to Coherus’s acquisition of Surface in a transaction that closed for roughly $66.9M (cash plus net cash at closing).[3][5]

Core Differentiators

• Multi‑target TME focus: Designed a pipeline to hit multiple complementary TME mechanisms (IL‑27, CD39, CD73, CCR8, PVRIG) rather than a single checkpoint approach.[3][4]
  - Clinic‑stage portfolio with partnerships: Advanced several candidates to clinical stages and secured external collaborations (e.g., Novartis, GlaxoSmithKline), improving development de‑risking and commercial optionality.[4][3]
  - Translational biology and antibody discovery: Emphasized deep TME biology and generation of diverse, high‑quality therapeutic antibodies to explore novel targets and mechanisms.[2]
  - Exit and value capture: Successful transition from venture‑backed startup to acquisition by Coherus, showing an operational path from discovery to strategic exit in oncology biotech.[5]

Role in the Broader Tech/biotech Landscape

• Trend alignment: Surface rode the next‑generation immuno‑oncology trend that shifts focus from PD‑1/CTLA‑4 checkpoints to the tumor microenvironment and innate/adaptive cross‑talk to expand responder populations.[2][3]
  - Timing and market forces: The limited durable response rates from first‑generation checkpoint inhibitors created scientific and commercial demand for complementary TME modulators, making Surface’s timing favorable for partnerships and acquisition.[2][5]
  - Influence on ecosystem: By progressing multiple novel mechanisms and securing pharma partnerships, Surface provided a model for target‑centric biotech that can attract strategic collaborations and exits, reinforcing investor appetite for mechanistic, clinic‑enabling oncology startups.[3][5]

Quick Take & Future Outlook

• Near‑term path (post‑acquisition): Surface’s assets were folded into Coherus’s I‑O strategy—Coherus intends to advance SRF388 (casdozo) and SRF114 (CHS‑114/anti‑CCR8) and integrate these TME programs into broader clinical development plans.[5]
  - Shaping trends: Continued interest in TME biology, combination regimens, and biomarker‑driven patient selection will determine the clinical and commercial prospects of Surface’s former assets.[2][5]
  - How influence may evolve: If the clinical readouts from IL‑27, CCR8, CD39/CD73 programs show meaningful survival benefits or enable new combinations with PD‑(L)1 or other modalities, these assets could become cornerstone therapies that validate TME‑first development strategies and spur further investment into similar startups.[3][5]

Quick reiteration: Surface Oncology built a focused, clinic‑stage immuno‑oncology portfolio targeting the tumor microenvironment, attracted major pharma collaborations, and was acquired by Coherus—offering a clear example of how mechanistic TME science can translate into strategic value for investors and acquirers in the oncology biotech ecosystem.[3][5]